News

Babraham adds five science start-ups to LiveLabs space

News

Evelina Grecenko

12 June 2025

Life sciences, Offices

Cambridge

Five life science start-ups have found new home within communal LiveLabs space at Babraham Research Campus.

The move forms part of the Cambridge campus’s annual accelerator programme, comprising a bespoke eight-week taught programme of scientific, business and technical support, up to 12 months free lab space and £10,000 non-diluted funding. Since its inception, the programme has supported 32 early-stage enterprises.

New joiners include AAB Research, a developer behind engineered extracellular vesicles; AmnioCam, which is set to create a stem cell-based alternative to placental donor-harvested amniotic cells; Cycle Therapeutics, a drug discovery firm focused on endometriosis; MabGalaxy, an antibody medicines firm; and Sysora Health, a gum disease solution developer.

The innovators will be supported by the campus throughout the year across commercialisation strategy, work towards experimental inflection points, proof of concept and the establishment of technical readiness.

Louise Jopling, chief scientific and innovation officer at Babraham Research Campus, said: “Having collectively raised over £100m to date, delivered a 1.9x return on investment and created over 117 jobs, Accelerate@Babraham companies have made a contribution to health and economic growth across our region and the UK as a whole. The current cohort now has the opportunity to follow in these footsteps, and we play our part in supporting and nurturing their success.”

Babraham Research Campus, spanning 450 acres, is owned by the Babraham Institute and the Biotechnology and Biological Sciences Research Council, and is operated in partnership with One Nucleus, Kadans and BioMed.

Image © Babraham Research Campus. Back row (Left to right) Lucy Rowbotham (Sysora Health), Vivian Wong (MabGalaxy), Andy Wood (MabGalaxy), Kevin Chalut (Cycle Therapeutics), Jenny Hirst (Programme Manager, Accelerate@Babraham). Front row (Left to right) Eline Koers (AAB Research), Laura Bergamaschi (MabGalaxy), Dmitry Veprintsev (AAB Research), Aljona Kolmogorova (AmnioCam)

Send feedback to Evelina Grecenko

Babraham Research Campus, Cambridge, life science

Five life science start-ups have found new home within communal LiveLabs space at Babraham Research Campus. The move forms part of the Cambridge campus’s annual accelerator programme, comprising a bespoke eight-week taught programme of scientific, business and technical support, up to 12 months free lab space and £10,000 non-diluted funding. Since its inception, the programme has supported 32 early-stage enterprises. New joiners include AAB Research, a developer behind engineered extracellular vesicles; AmnioCam, which is set to create a stem cell-based alternative to placental donor-harvested amniotic cells; Cycle Therapeutics, a drug discovery firm focused on endometriosis; MabGalaxy, an antibody medicines firm; and Sysora Health, a gum disease solution developer. The innovators will be supported by the campus throughout the year across commercialisation strategy, work towards experimental inflection points, proof of concept and the establishment of technical readiness. Louise Jopling, chief scientific and innovation officer at Babraham Research Campus, said: “Having collectively raised over £100m to date, delivered a 1.9x return on investment and created over 117 jobs, Accelerate@Babraham companies have made a contribution to health and economic growth across our region and the UK as a whole. The current cohort now has the opportunity to follow in these footsteps, and we play our part in supporting and nurturing their success.” Babraham Research Campus, spanning 450 acres, is owned by the Babraham Institute and the Biotechnology and Biological Sciences Research Council, and is operated in partnership with One Nucleus, Kadans and BioMed. Image © Babraham Research Campus. Back row (Left to right) Lucy Rowbotham (Sysora Health), Vivian Wong (MabGalaxy), Andy Wood (MabGalaxy), Kevin Chalut (Cycle Therapeutics), Jenny Hirst (Programme Manager, Accelerate@Babraham). Front row (Left to right) Eline Koers (AAB Research), Laura Bergamaschi (MabGalaxy), Dmitry Veprintsev (AAB Research), Aljona Kolmogorova (AmnioCam)